48. 原発性抗リン脂質抗体症候群 Primary antiphospholipid syndrome Clinical trials / Disease details
臨床試験数 : 5 / 薬物数 : 6 - (DrugBank : 4) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05671757 (ClinicalTrials.gov) | March 12, 2023 | 20/12/2022 | Daratumumab in Primary Antiphospholipid Syndrome | Targeting CD38 With Daratumumab in Primary Antiphospholipid Syndrome: A Phase 1b Dose Escalation Safety Trial (ITN093AI) | Autoimmune Disorders | Biological: Daratumumab | National Institute of Allergy and Infectious Diseases (NIAID) | Immune Tolerance Network (ITN);PPD;Rho Federal Systems Division, Inc. | Not yet recruiting | 18 Years | 65 Years | All | 22 | Phase 1/Phase 2 | United States |